|
Torrent Pharmaceuticals and Zydus Lifesciences announced that they have entered into a licensing and supply agreement to co-market Saroglitazar Mg for the treatment of Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. As the only approved drug for NASH and NAFLD in the country, Saroglitazar Magnesium is likely to play a key role in managing and mitigating these progressive and prevalent liver disorders.
With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden and offers greater convenience for patients.
Under the terms of this agreement, Torrent will have semi-exclusive rights to co-market the product in India under the brand name VORXAR®. Zydus launched the drug under the brand
names Lipaglyn® and Bilypsa® and will continue to market them. Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.
Saroglitazar Mg, is an innovative drug from Zydus approved by the DCGI to treat chronic liver diseases such as, Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD). India is the first country to have a drug approved for these unmet medical needs.
Currently, there is no approved drug for the treatment of NASH and NAFLD anywhere else in the world.
|